Spencer S. Lee Sells 1,000 Shares of Chemed Corp. (CHE) Stock

Chemed Corp. (NYSE:CHE) insider Spencer S. Lee sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $232.27, for a total value of $232,270.00. Following the sale, the insider now owns 35,809 shares in the company, valued at approximately $8,317,356.43. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of Chemed Corp. (NYSE CHE) opened at $247.53 on Monday. The company has a current ratio of 0.50, a quick ratio of 0.48 and a debt-to-equity ratio of 0.15. Chemed Corp. has a 1 year low of $148.84 and a 1 year high of $248.31. The firm has a market capitalization of $3,950.00, a price-to-earnings ratio of 30.48, a P/E/G ratio of 5.23 and a beta of 1.16.

Chemed (NYSE:CHE) last announced its quarterly earnings data on Thursday, October 26th. The company reported $2.15 earnings per share for the quarter, topping the consensus estimate of $2.00 by $0.15. Chemed had a return on equity of 27.69% and a net margin of 4.62%. The business had revenue of $417.40 million during the quarter, compared to the consensus estimate of $414.34 million. During the same period in the prior year, the company earned $1.73 EPS. Chemed’s revenue for the quarter was up 6.3% on a year-over-year basis. analysts predict that Chemed Corp. will post 4.73 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Monday, December 4th. Shareholders of record on Monday, November 13th will be given a $0.28 dividend. The ex-dividend date of this dividend is Friday, November 10th. This represents a $1.12 annualized dividend and a yield of 0.45%. Chemed’s dividend payout ratio is presently 24.94%.

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in Chemed by 1.9% in the second quarter. Vanguard Group Inc. now owns 1,830,711 shares of the company’s stock valued at $374,435,000 after purchasing an additional 34,938 shares during the last quarter. Acadian Asset Management LLC raised its position in Chemed by 1.3% in the second quarter. Acadian Asset Management LLC now owns 579,170 shares of the company’s stock valued at $118,454,000 after purchasing an additional 7,636 shares during the last quarter. State Street Corp raised its position in Chemed by 1.8% in the second quarter. State Street Corp now owns 453,605 shares of the company’s stock valued at $92,782,000 after purchasing an additional 8,238 shares during the last quarter. Investec Asset Management LTD increased its stake in shares of Chemed by 1.8% in the third quarter. Investec Asset Management LTD now owns 323,231 shares of the company’s stock valued at $65,309,000 after buying an additional 5,717 shares during the period. Finally, Voya Investment Management LLC increased its stake in shares of Chemed by 39.7% in the second quarter. Voya Investment Management LLC now owns 214,764 shares of the company’s stock valued at $43,926,000 after buying an additional 61,056 shares during the period. Hedge funds and other institutional investors own 97.72% of the company’s stock.

A number of research analysts have commented on CHE shares. ValuEngine lowered Chemed from a “buy” rating to a “hold” rating in a report on Friday. Zacks Investment Research upgraded Chemed from a “hold” rating to a “buy” rating and set a $251.00 target price for the company in a research report on Thursday, November 2nd. TheStreet upgraded Chemed from a “c+” rating to an “a-” rating in a research report on Friday, October 27th. Royal Bank Of Canada upped their target price on Chemed to $232.00 and gave the company a “sector perform” rating in a research report on Tuesday, October 31st. Finally, Oppenheimer upped their target price on Chemed from $220.00 to $225.00 and gave the company an “outperform” rating in a research report on Friday, October 27th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $236.00.

TRADEMARK VIOLATION WARNING: This piece of content was posted by Week Herald and is the property of of Week Herald. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://weekherald.com/2017/12/04/chemed-corp-che-insider-spencer-s-lee-sells-1000-shares-of-stock.html.

About Chemed

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Insider Buying and Selling by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply